Document Detail


Negative effects of anemia on quality of life and its improvement by complete correction of anemia by administration of recombinant human erythropoietin in posttransplant patients.
MedLine Citation:
PMID:  19352589     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Anemia is a common complication in posttransplant patients (posttransplant anemia: PTA). We tested the hypothesis that targeting hemoglobin (Hb) over 13.3 g/dl by administration of recombinant human erythropoietin (rHuEPO-ad) has positive impact on quality of life (QOL). METHODS: Twenty-four patients, whose initial Hb and estimated glomerular filtration rate (eGFR) were 10.5 +/- 0.2 g/dl and 48.5 +/- 2.7 ml/(min 1.73 m2), respectively, were enrolled in the present study. Physical and mental QOL in these patients before and after rHuEPO-ad were acquired and summarized as physical summary sore (PSC) and mental summary sore (MSC), respectively, by the 36-item Short Form (SF-36), an international questionnaire for analysis of QOL. RESULTS: Before rHuEPO-ad, posttransplant patients had preserved MSC (54.1 +/- 2.3) but impaired PSC (32.6 +/- 3.2). rHuEPO-ad for 6 months increased their Hb to 13.7 +/- 0.3 g/dl. This was accompanied by improvement of PSC (49.1 +/- 2.1: P < 0.01 versus before rHuEPO-ad). MSC was preserved during rHuEPO-ad (54.4 +/- 1.6: NS versus before rHuEPO-ad). There was inverse correlation between initial PSC or MSC and responses of these parameters to rHuEPO-ad (PSC, P = 0.007; MSC, P = 0.009). Patients whose initial PSC was lower than 39.6 or whose initial MSC was lower than 39.4 were expected to improve their PSC or MSC by more than 10 by rHuEPO-ad. CONCLUSIONS: Anemia in posttransplant patients has negative impacts on their QOL. Scoring mental and physical QOL by SF-36 in posttransplant patients is useful to identify groups of patients whose QOL could be improved by rHuEPO-ad.
Authors:
Noritaka Kawada; Toshiki Moriyama; Naotsugu Ichimaru; Ryoichi Imamura; Isao Matsui; Yoshitsugu Takabatake; Yasuyuki Nagasawa; Yoshitaka Isaka; Yasuyuki Kojima; Yukito Kokado; Hiromi Rakugi; Enyu Imai; Shiro Takahara
Related Documents :
1939699 - Intellectual loss in alzheimer's dementia and wais-r intrasubtest scatter.
11493169 - Basal ganglia metabolite abnormalities in minor motor disorders associated with human i...
20491609 - Effect of brain-derived neurotrophic factor val66met polymorphism and serum levels on t...
10932269 - Unilateral spatial neglect in ad: significance of line bisection performance.
1491839 - Cognition and 99tcm-hmpao spect in parkinson's disease.
762369 - Dihydroergotoxine: 6-mg versus 3-mg dosage in the treatment of senile dementia. prelimi...
19570519 - Comparison of quality-of-life instruments in adults with strabismus.
22305109 - Dysfunctional forward model mechanisms and aberrant sense of agency in obsessive-compul...
1141959 - Reversible central nervous system dysfunction in folate deficiency.
Publication Detail:
Type:  Clinical Trial; Journal Article     Date:  2009-04-08
Journal Detail:
Title:  Clinical and experimental nephrology     Volume:  13     ISSN:  1437-7799     ISO Abbreviation:  Clin. Exp. Nephrol.     Publication Date:  2009 Aug 
Date Detail:
Created Date:  2009-08-06     Completed Date:  2009-10-27     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9709923     Medline TA:  Clin Exp Nephrol     Country:  Japan    
Other Details:
Languages:  eng     Pagination:  355-60     Citation Subset:  IM    
Affiliation:
Department of Nephrology, Osaka University Graduate School of Medicine, Osaka, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Anemia / blood,  drug therapy*,  etiology,  physiopathology,  psychology
Biological Markers / blood
Creatine / blood
Erythropoietin, Recombinant / therapeutic use*
Female
Glomerular Filtration Rate
Hematinics / therapeutic use*
Hemoglobins / metabolism
Humans
Kidney Transplantation / adverse effects*
Male
Middle Aged
Patient Selection
Prospective Studies
Psychiatric Status Rating Scales
Quality of Life*
Questionnaires
Time Factors
Treatment Outcome
Chemical
Reg. No./Substance:
0/Biological Markers; 0/Erythropoietin, Recombinant; 0/Hematinics; 0/Hemoglobins; 57-00-1/Creatine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Sargramostim in patients with Crohn's disease: results of a phase 1-2 study.
Next Document:  Prevalence of neutralising antibodies in patients treated with botulinum toxin type A for spasticity...